Loading clinical trials...
Loading clinical trials...
A Phase II Study to Evaluate the Efficacy of IdeS (IgG Endopeptidase) to Desensitize Transplant Patients With a Positive Crossmatch Test
Conditions
Interventions
IdeS
Kidney transplantation
Locations
5
United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
The Johns Hopkins Hospital
Baltimore, Maryland, United States
New York University School of Medicine
New York, New York, United States
Necker Hospital
Paris, France
Uppsala University Hospital
Uppsala, Sweden
Start Date
June 1, 2016
Primary Completion Date
December 12, 2017
Completion Date
July 3, 2018
Last Updated
May 20, 2021
NCT06314503
NCT06438445
NCT03640026
NCT05968391
NCT06288451
NCT03380962
Lead Sponsor
Hansa Biopharma AB
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions